title: [Tropisetron for the prevention of nausea and vomiting during chemotherapy: multicenter clinical study].
abstract: The antiemetic effect of tropisetron was studied in 97 cancer patients (67 men, 30 women) receiving cisplatin in doses of 75 mg/m2 or higher. On 279 chemotherapy cycles studied (max 6 per patient) 5 mg of tropisetron was administered once a day i.v on day 1 and p.o. on days 2 to 6. Efficacy preventing vomiting and nausea was measured in 24 hour period as: complete control O episodes, major control 1 to 2 episodes, minor control 3 to 4 episodes and no control 5 or more episodes. Satisfactory vomiting control (complete and major) was 69%, 63%, 82%, 88%, 96% and 96% in days 1 to 6 of cycle 1. Satisfactory nausea control (complete and major) for the same days was 70%, 66%, 72%, 85%, 92% and 97%. Similar data was obtained for the subsequent cycles. Complete vomiting control was obtained in 47%, 35%, 56%, 72%, 81% and 84% and for nausea in 42%, 39%, 48%, 64%, 81% and 87%. 19 patients presented adverse effects (19.6%). Only 2 headache episodes had a definite relation with the antiemetic drug. 12 patients discontinued the medication; 6 due to drug inefficacy, 2 to illness unrelated to the drug, 1 to lack of collaboration, and 3 due to other reasons. We conclude that tropisetron allows satisfactory control of acute and delayed vomiting in a high percentage of patients treated with high doses of cisplatin. The drug does not have significant secondary effects. Tropisetron administration in only one daily dose implies an evident advantage and a treatment cost reduction.
authors.affiliation: Hospital San Juan de Dios, Hospital Clínico de la Universidad de Chile, Santiago de Chile.
authors.forename: J
authors.initials: J
authors.lastname: Gutiérrez
authors.forename: L
authors.initials: L
authors.lastname: Bronfman
authors.forename: C
authors.initials: C
authors.lastname: Cao
authors.forename: A
authors.initials: A
authors.lastname: Vásquez
authors.forename: L
authors.initials: L
authors.lastname: Derio
authors.forename: J
authors.initials: J
authors.lastname: Rosas
authors.forename: C
authors.initials: C
authors.lastname: del Castillo
authors.forename: M
authors.initials: M
authors.lastname: Yáñez
authors.forename: M
authors.initials: M
authors.lastname: Fodor
authors.forename: J
authors.initials: J
authors.lastname: Gallardo
authors.forename: B
authors.initials: B
authors.lastname: Cerda
authors.forename: R
authors.initials: R
authors.lastname: Torres
authors.forename: L
authors.initials: L
authors.lastname: Orlandi
authors.forename: F
authors.initials: F
authors.lastname: Orlandi
authors.forename: S
authors.initials: S
authors.lastname: Kleinman
authors.forename: C
authors.initials: C
authors.lastname: Vogel
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000932:Antiemetics / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000009:adverse effects*; D005260:Female; D006801:Humans; D007211:Indoles / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009325:Nausea / Q000139:chemically induced / Q000517:prevention & control*; D009369:Neoplasms / Q000188:drug therapy*; D000077526:Tropisetron; D014839:Vomiting / Q000139:chemically induced / Q000517:prevention & control*
chemical_list: D000932:Antiemetics; D000970:Antineoplastic Agents; D007211:Indoles; D000077526:Tropisetron